UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez
Company Presents HOPE-B Data At R&D Day
The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.
The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.